消木丹联合瑞美替罗对代谢相关脂肪性肝病模型小鼠的干预作用OA
Effect of Xiaomudan combined with resmetirom on metabolic dysfunction-associated fatty liver disease in mice
目的:观察消木丹联合瑞美替罗对代谢相关脂肪性肝病(MAFLD)模型小鼠的干预作用.方法:30只小鼠随机分为对照组(n=6)和造模组(n=24),造模组小鼠采用蛋氨酸胆碱缺乏(MCD)饮食6周构建MAFLD小鼠模型,第4周开始随机分为模型组、瑞美替罗(5 mg/kg)组、消木丹(20 g/kg)组、瑞美替罗联合消木丹组,分别灌胃相应药物至6周末.检测血脂及肝功能,包括总胆固醇(TC)、甘油三酯(TG)、游离脂肪酸(NEFA)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、血清胰岛素抵抗指数.肝组织病理形态学评估采用HE染色、油红O染色、天狼猩红染色;细胞实验以油红O染色观察药物对肝细胞脂质沉积的影响.结果:与模型组相比,各用药组小鼠肝组织TC、TG、NEFA水平显著降低(P<0.05或P<0.01);血清ALT、AST水平均显著降低(P<0.01);血清空腹胰岛素水平及胰岛素抵抗指数均显著回调(P<0.05或P<0.01);肝组织及肝细胞的病理损伤及脂滴沉积均较模型组显著改善;联合用药组改善效果均优于单独给药组(P<0.01).结论:消木丹联合瑞美替罗用药可显著改善MAFLD模型小鼠肝损伤和脂肪沉积,疗效优于单药.
Objective:To investigate the effect of Xiaomudan combined with resmetirom on metabolic dysfunction-associated fatty liver disease(MAFLD)in mice.Methods:MAFLD mouse model was established by MCD diet and divided into Resmetirom(5 mg/kg)group and Xiaomudan(20 g/kg)group,and the Resmetirom combined with Xiaomudan group.In the animal model,liver tissue lipid levels(TC,TG,and NEFA),serum aminotransferase(ALT,AST),serum insulin resistance index,and liver tissue pathological staining(hematoxylin and eosin,oil red O,and Sirius red staining)were detected to observe the therapeutic effect of drugs.The effect of drugs on lipid deposition in hepatocytes was observed by oil red O staining in the cell model.Results:Compared with the model group,the levels of TC,TG,and NEFA in the liver tissue of each medication group were significantly decreased(P<0.05,0.01).The serum levels of ALT and AST were significantly decreased(P<0.01).The levels of serum fasting insulin and insulin resistance index were significantly decreased(P<0.05,0.01).The pathological damage of liver tissue and hepatocytes were significantly improved compared with the model group.Based on the above results,the improvement effect of combined treatment group was better than that of single treatment group(P<0.01).Conclusion:Xiaomudan combined with Resmetirom exerts a beneficial effect on improving MAFLD mice.
黄倩;杨浩;张小曼;李木子;王宁;闫曙光;郑旭锐;李京涛
陕西中医药大学基础医学院(陕西 咸阳,712046)陕西中医药大学第一临床医学院陕西中医药大学第一临床医学院陕西中医药大学第一临床医学院陕西中医药大学附属医院肝病医院陕西中医药大学基础医学院(陕西 咸阳,712046)陕西中医药大学基础医学院(陕西 咸阳,712046)陕西中医药大学附属医院肝病医院
医药卫生
代谢相关脂肪性肝病瑞美替罗消木丹联合用药
metabolic dysfunction-associated fatty liver diseaseresmetiromXiaomudancombination therapy
《中西医结合肝病杂志》 2026 (8)
973-977,5
国家自然科学基金(No.82374418),中医药防治肝病"炎-癌"转变创新团队(No.2019-YL05),陕西省教育厅科学研究计划项目(No.24JP046),陕西省自然科学基础研究计划项目(No.2026JC-YBQN-1195)
评论